Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer

Subjects

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2019;11:1–5.

    Google Scholar 

  2. 2.

    Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2019;38:395–405.

    Article  Google Scholar 

  3. 3.

    Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, O’Neal T, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2019;14:1–0.

    Google Scholar 

  4. 4.

    Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (Lond. Engl). 2018;392:2353–66.

    Article  Google Scholar 

  5. 5.

    Connor MJ, Ahmed HU. Adjuvant treatments to the local tumour for metastatic prostate cancer: assessment of novel treatment algorithms (IP2-ATLANTA) NCT03763253. https://clinicaltrials.gov/ct2/show/NCT03763253

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to M. J. Connor.

Ethics declarations

Conflict of interest

MJC has received funding from the Wellcome Trust and University College London Hospital (UCLH) Charity. MW: None. HUA reports receipt of grant funding and personal fees from SonaCare Medical Inc, grant funding from Trod Medical, and grant funding and personal fees from Sophiris Bio Inc. HUA also receives core funding from the UK National Institute of Health Research Imperial Biomedical Research Centre and grants from Wellcome Trust, MRC (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation and Imperial Healthcare Charity.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Connor, M.J., Winkler, M. & Ahmed, H.U. Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis (2020). https://doi.org/10.1038/s41391-020-0216-4

Download citation